In immune-competent mice, orally administered CA-170 inhibits the growth of syngeneic tumors, enhances peripheral T cell activation, and promotes the activation of tumor infiltrating CD8+ T cells in a dose-dependent manner. This evidence concerns the gene CD8A and neoplasm.